The single largest global registry will collect and analyze stroke-inducing blood clots removed from the brain by thrombectomy. The Excellent Registry will enroll up to 1,000 ischemic stroke patients in 50 clinical sites in the United States and Europe.
Evidence will be collected from patients, and clots will be preserved and studied to determine how clot characteristics including size, composition, and density may affect patient comorbidities, clinical outcomes, and revascularization rates.
Advances in thrombectomy have made it standard practice, but 20% or more of ischemic stroke cases are resistant to the procedure because of the nature and composition of certain blood clots.
Extensive clot research led to the development of the Embotrap II device (CERENOVUS, Irvine, CA), which has a dual-layer design that allows doctors to engage and control a broad range of clots with minimal compression during removal. The device was approved by the US Food and Drug Administration (FDA) earlier this year and has been available in Europe since 2016.
"This is a landmark registry study that will provide real-world data on the Embotrap II device while advancing the scientific community's understanding of how variations in blood clots correlate with treatment and outcomes," said Daniella Cramp, president of CERENOVUS. "We believe thoughtful and extensive research into the science of blood clots is the key to developing the most effective endovascular treatments and bringing benefits to the greatest number of stroke patients."Next Story